Research programme: 3D printed nanomedicines - Aprecia/Nanoform
Latest Information Update: 28 May 2025
At a glance
- Originator Aprecia Pharmaceuticals; Nanoform
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2025 No recent reports of development identified for research development in Unspecified in Finland (PO)
- 28 May 2025 No recent reports of development identified for research development in Unspecified in USA (Buccal)
- 28 May 2025 No recent reports of development identified for research development in Unspecified in USA (PO)